Entropy Neurodynamics Limited (TYPTF)

Market Cap	36.76M +44.1%
Revenue (ttm)	1.04M +19.2%
Net Income	-3.50M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,963
Average Volume	175,266
Open	0.0212
Previous Close	0.0200
Day's Range	0.0122 - 0.0212
52-Week Range	0.0061 - 0.0343
Beta	n/a
RSI	50.35
Earnings Date	Sep 30, 2025

About Entropy Neurodynamics

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: TYPTF

Financial Performance

In fiscal year 2025, Entropy Neurodynamics's revenue was 1.58 million, an increase of 19.17% compared to the previous year's 1.33 million. Losses were -5.33 million, -27.66% less than in 2024.

Financial numbers in AUD